Search research articles
Contact Us
Filters
Showing results (271-280 of 395) with videos related to
Page
of 40
Sort By:
The Journal of Biological Chemistry
|
June 6, 1997
Inhibition of HIV-1 replication using a mutated tRNALys-3 primer
Y Lu, V Planelles, X Li, et al.
Bulletin of the World Health Organization
|
September 2, 2024
Home visits versus fixed-site care by community health workers and child survival: a cluster-randomized trial, Mali
Jenny Liu, Emily Treleaven, Caroline Whidden, et al.
BMJ Open
|
August 29, 2019
Proactive community case management and child survival: protocol for a cluster randomised controlled trial
Caroline Whidden, Emily Treleaven, Jenny Liu, et al.
Future Oncology (London, England)
|
August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
Environmental Management
|
September 2, 2018
Leveraging Big Data Towards Functionally-Based, Catchment Scale Restoration Prioritization
John P Lovette, Jonathan M Duncan, Lindsey S Smart, et al.
Clinical and Vaccine Immunology : CVI
|
May 15, 2009
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay
Kazutoyo Miura, Hong Zhou, Ababacar Diouf, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 29, 2020
Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics
Fei Li Kuang, Bryan F Curtin, Hawwa Alao, et al.
European Urology
|
June 26, 2012
BRAF mutations in metanephric adenoma of the kidney
Toni K Choueiri, John Cheville, Emanuele Palescandolo, et al.
Future Oncology (London, England)
|
January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
European Urology Focus
|
July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma
Guillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
Page
of 40
Search research articles
Search
Showing results (271-280 of 395) with videos related to
Sort By:
Page
of 40
The Journal of Biological Chemistry
|
June 6, 1997
Inhibition of HIV-1 replication using a mutated tRNALys-3 primer
Y Lu, V Planelles, X Li, et al.
Bulletin of the World Health Organization
|
September 2, 2024
Home visits versus fixed-site care by community health workers and child survival: a cluster-randomized trial, Mali
Jenny Liu, Emily Treleaven, Caroline Whidden, et al.
BMJ Open
|
August 29, 2019
Proactive community case management and child survival: protocol for a cluster randomised controlled trial
Caroline Whidden, Emily Treleaven, Jenny Liu, et al.
Future Oncology (London, England)
|
August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
Environmental Management
|
September 2, 2018
Leveraging Big Data Towards Functionally-Based, Catchment Scale Restoration Prioritization
John P Lovette, Jonathan M Duncan, Lindsey S Smart, et al.
Clinical and Vaccine Immunology : CVI
|
May 15, 2009
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay
Kazutoyo Miura, Hong Zhou, Ababacar Diouf, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 29, 2020
Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics
Fei Li Kuang, Bryan F Curtin, Hawwa Alao, et al.
European Urology
|
June 26, 2012
BRAF mutations in metanephric adenoma of the kidney
Toni K Choueiri, John Cheville, Emanuele Palescandolo, et al.
Future Oncology (London, England)
|
January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
European Urology Focus
|
July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma
Guillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
Page
of 40